IPO Year: 2023
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2024 | $118.00 | Overweight | Morgan Stanley |
| 5/21/2024 | $65.00 | Overweight | JP Morgan |
| 4/9/2024 | $65.00 | Overweight | Cantor Fitzgerald |
| 10/19/2023 | $90.00 | Mkt Outperform | JMP Securities |
| 7/27/2023 | $58.00 | Overweight | Piper Sandler |
| 5/25/2023 | $34.00 → $41.00 | Buy | Jefferies |
| 2/28/2023 | $33.00 | Outperform | SVB Securities |
| 2/28/2023 | $50.00 | Buy | Guggenheim |
| 2/28/2023 | $34.00 | Buy | Jefferies |
| 2/28/2023 | $40.00 | Outperform | BMO Capital Markets |
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference Format:Presentation and fireside chat Date/time:Wednesday, November 20 at 8:00 a.m. GMT The live and archived webcast will be accessible from the company's website at https://ir.structuretx.com/eve
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX. Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity TreatmentPoster Number: Poster 128Date/Time: Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT Location: Exhibit Hall 4 Title: Drug Design Principles and Pharmacokinetics/Pharmacodynamics of GSBR-1290, a Small Molecule GLP-
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase
SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat: Thursday, September 5 at 10:00 a.m. EDT Cantor Fitzgerald Global Healthcare Conference 2024Fireside chat: Thursday, September 19 at 9:10 a.m. EDT Live and archived webcasts of the fireside chats will be accessible from the company's website https://ir.structuretx.com/events-presentations/even
GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter of 2024 Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary d
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 additional ADSs, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underw
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be approximately $476.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the un
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
3 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
3 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
3 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
4 - Structure Therapeutics Inc. (0001888886) (Issuer)
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase
SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the Biotechnology Innovation Organization (BIO) Board. He recently served as President and Chief Executive Officer of Global Blood Therapeutics until its acquisition by Pfizer in 2022. "Ted has a deep passion for making medicines accessible to all and has spent much of his acc
10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
10-Q - Structure Therapeutics Inc. (0001888886) (Filer)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
144 - Structure Therapeutics Inc. (0001888886) (Subject)
424B4 - Structure Therapeutics Inc. (0001888886) (Filer)
EFFECT - Structure Therapeutics Inc. (0001888886) (Filer)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)
SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)
Morgan Stanley initiated coverage of Structure Therapeutics with a rating of Overweight and set a new price target of $118.00
JP Morgan initiated coverage of Structure Therapeutics with a rating of Overweight and set a new price target of $65.00
Cantor Fitzgerald initiated coverage of Structure Therapeutics with a rating of Overweight and set a new price target of $65.00
JMP Securities initiated coverage of Structure Therapeutics with a rating of Mkt Outperform and set a new price target of $90.00
Piper Sandler initiated coverage of Structure Therapeutics with a rating of Overweight and set a new price target of $58.00
Jefferies resumed coverage of Structure Therapeutics with a rating of Buy and set a new price target of $41.00 from $34.00 previously
SVB Securities initiated coverage of Structure Therapeutics with a rating of Outperform and set a new price target of $33.00
Guggenheim initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00
Jefferies initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $34.00
BMO Capital Markets initiated coverage of Structure Therapeutics with a rating of Outperform and set a new price target of $40.00
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study, in both cases at 12 weeks GSBR-1290 demonstrated generally favorable safety and tolerability results with low AE-related study discontinuations Pharmacokinetic data support dose proportional exposure and once-daily oral dosing of GSBR-1290 36-week Phase 2b study in obesity on track to begin in the fourth quarter of 2024 Company to host conference call today at 8:30 a.m. ET SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clin
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity Topline Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and weight at 12 weeks Interim Phase 2a data from obesity cohort demonstrate significant reduction in weight at 8 weeks; full 12-week obesity data expected in second quarter 2024 with Phase 2b study initiation on track for second half 2024 Program update includes results from Japanese bridging study a
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily dosing Topline data from Phase 2a type 2 diabetes cohort expected in latter half of fourth quarter 2023; topline data from obesity cohort now expected in the first half 2024 Phase 2b studies in type 2 diabetes and obesity planned for initiation in 2024 Company to host conference call today, September 29 at 8:30 a.m. ET SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral sma
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday. What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks. This data is better compared to existing competitors. Also Read: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Beco
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 300 points on Wednesday. Shares of ASML Holding N.V. (NASDAQ:ASML) fell in today's pre-market trading following the release of second-quarter results. The Dutch company reported a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts' expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024. ASML shares dipped 6.8% to $995.90 i
Structure Therapeutics's (NYSE:GPCR) short percent of float has risen 31.9% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 19.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.48 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.
BMO Capital analyst Evan David Seigerman maintains Structure Therapeutics (NASDAQ:GPCR) with a Outperform and raises the price target from $83 to $100.